Equity Research · Investment Report

Ajinomoto Co., Inc.

味の素株式会社 · TSE Prime: 2802 · Consumer Staples / Amino-Science

Rating: BUY Target: ¥6,800 Current: ¥5,566 Upside: +22%

Report date

18 Aug 2026

Data: FY2022–FY2026 actuals + FY2027E guidance

01 · Executive Summary

Executive Summary

Ajinomoto is a 117-year-old Japanese consumer-staples giant (seasonings, frozen foods) that has quietly built a quasi-monopoly in ABF (Ajinomoto Build-up Film), the insulating film essential to every advanced AI/CPU/GPU semiconductor package — global share >95%, ~100% in the high-end segment. The market is only now re-rating this hidden semiconductor asset as AI demand explodes and activist pressure unlocks pricing power.

Rating

BUY

Target / Current (¥)

6,800 / 5,566

Upside

+22%

P/E (TTM)

~39×

FY2026 Business Profit

¥181.2B

Div. Yield

~0.9%

Company at a glance

Founded 1909 (umami/MSG inventor) ~¥1.58T net sales (FY2026) Overseas revenue ~64% 3 reportable segments + Other ABF >95% global share 117 plants, 121 entities, 31 countries Amino-Science core platform

02 · Investment Thesis

Investment Thesis — Three Pillars

① Healthcare / ABF — the AI semiconductor monopoly Strong

>95% global ABF share (~100% high-end) for FC-BGA substrates used in every NVIDIA/Intel/AMD GPU & CPU; sole real competitor Sekisui (<5%, low-end only).
Price hikes of ~30% announced May 2026 (effective Q3) — near-zero demand elasticity (ABF <0.1% of a GPU BOM cost); pushed by activist Palliser Capital.
Supply-demand gap projected ~10% (2026H2) → 21% (2027) → 42% (2028); capacity at 100% utilization, no new plant until ~2032.
Functional-materials margin >50%; Healthcare segment BP +45% YoY to ¥66.2B in FY2026 (19.4% margin).

Risk: ABF volume is tied to one cycle — an AI-capex correction hits it hard; glass-substrate shift post-2028 is a watch item; customer base geographically concentrated (US/Taiwan).

② Seasonings & Foods — the reliable cash cow re-rating Strong

Structural profit base: ¥143.0B BP, record 15.3% margin in FY2026 (~2/3 of segment profit).
Dominant #1 franchises: umami 96%, dashi 58%, consommé 78%, menu seasonings 28%; overseas #1 in Thailand/Philippines/Vietnam/Brazil.
Defensive, staple demand; Japan price increases + emerging-market volume drive margin; premiumization (Cook Do 極) adds mix.
Low cyclicality diversifies the group's AI-cycle concentration.

Risk: Japan market mature; raw-material cost inflation caps overseas margin; MSG price war vs Chinese producers is a structural threat.

③ Capital reform & shareholder returns Medium

Activist Palliser Capital (London) built a major stake, demanding ABF price hikes and electronics-business separation — management complied on pricing and raised guidance.
Buyback: board authorized up to 30M shares / ¥80B (Nov 2025); ~9.7M shares / ¥37.6B bought by Apr 2026, to be cancelled.
Corporate actions: Malaysia Ajinomoto full-subsidiarization (Jun 2026), Altea CDMO divestiture, Forge Biologics (gene-therapy CDMO) M&A.
2030 roadmap: business-profit CAGR >10%, ROIC ~17%, ROE ~20%, EPS ~3× FY2022.

Risk: electronics separation may not materialize; buyback pace could slow; one-off gains (¥40.6B property sale) distort reported earnings.

Valuation view

At ¥5,566 the stock trades at ~39× TTM P/E and ~7× P/B — a premium to the packaged-foods sector (peers ~21×) that is justified by the ABF growth option and activist catalysts. Morningstar raised fair value ~20% on ABF strength (Q1 revenue +13% YoY). Analyst average target ≈ ¥6,032; our base target ¥6,800 embeds a ~34× forward P/E on ~¥200 forward EPS.

Company profile: sauces/seasonings ~60% of revenue; healthcare & frozen foods ~40%; ABF is the industry standard for semiconductor substrates.

03 · Financial Trajectory

Financial Trajectory

Consolidated P&L (¥ Million)

Item	FY22	FY23	FY24	FY25	FY26	FY27E
Net Sales	1,149,370	1,359,115	1,439,231	1,530,556	1,583,719	1,723,000
YoY %	+7.3	+18.2	+5.9	+6.3	+3.5	+8.8
Gross Profit	425,897	470,387	511,448	550,764	597,148	—
Gross Margin %	37.1	34.6	35.5	36.0	37.7	—
Business Profit	120,915	135,341	147,681	159,302	181,163	197,000
BP Margin %	10.5	10.0	10.3	10.4	11.4	11.4
Net Profit (parent)	75,725	94,065	87,121	70,272	134,675	—
EPS (¥)	69.71	87.99	83.72	69.77	138.36	—
DPS (¥, adj.)	26	34	37	40	24	—

Comparability: EPS/DPS shown on a post-2-for-1-split (Apr 2025) adjusted basis. Business profit is Ajinomoto's IFRS operating measure (excludes other operating income/expenses, incl. the ¥40.6B FY26 property-sale gain). FY2025 net profit was depressed by a ¥33.9B impairment (Altea CDMO).

Net Sales & Business Profit trend

Top line CAGR ~8.3% (FY22–26); business profit grew every single year to a record 11.4% margin in FY2026. FY2027E guidance: sales ¥1.723T (+8.8%), BP ¥197B (+8.7%).

04 · Business Deep Dive

Business Deep Dive — the 7 dimensions

① Product portfolio

Segment	Product family	Key brands / products	Margin profile
Seasonings & Foods	Seasonings	味の素® (umami), ほんだし®, KKコンソメ, ピュアセレクト® mayo, Cook Do®, Bistro Do®	High, stable
	Nutrition / processed	Knorr cup soups, Yum Yum noodles, Birdy, Blendy/MAXIM coffee (AGF)	Mid
	Solutions & Ingredients	Foodservice seasonings, processed amino acids, aspartame	Commodity / cyclical
Frozen Foods	Frozen	Gyoza, fried rice, noodles, desserts, yakitori (Japan + N. America)	Thin (2.9%)
Healthcare & Others	Pharma/food amino acids	Medical amino acids, culture media	High
	Bio-pharma (CDMO)	AJIPHASE®, CORYNEX®, AJICAP® (oligo/peptide/gene therapy via Forge)	High, growing
	Functional materials	ABF™ (semiconductor packaging film), adhesives, magnetic film, activated carbon	>50% margin
Other	—	Feed amino acids, sports nutrition (アミノバイタル®), personal care, medical food	Mixed

② Market position & moat

ABF semiconductor film — near-total monopoly

Ajinomoto (ABF)

>95%

Sekisui Chemical

~5%

Others (dry film etc.)

<1%

Moat = proprietary amino-acid resin recipe (from MSG byproduct R&D), ~4,000 patents (68% overseas, protection to ~2035), 2–3 yr 3-tier reliability qualification, and no substitute at the required AI spec.

Seasonings — Japan #1 franchises (FY25, consumer base)

Category	Brand	Share (rank)
Umami	味の素®	96% (1)
Dashi	ほんだし®	58% (1)
Consommé	KKコンソメ	78% (1)
Mayonnaise	ピュアセレクト®	28% (2)
Menu seasoning	Cook Do®	28% (1)

Overseas #1: Thailand umami ~90% / RosDee ~80%, Philippines ~100%, Vietnam ~60%, Indonesia 40–50%, Brazil Sazon ~70%.

③ Profit-driver decomposition (volume / price / cost / mix)

Segment FY2026 ΔBP	Volume	Price	Cost	Mix	Net ΔBP (¥M)
Seasonings & Foods	▲ overseas	▲ Japan price hikes	▼ raw-material cost	▲ premium (Cook Do 極)	+8,907
Healthcare & Others	▲▲ ABF volumes	▲▲ ~30% ABF price	stable	▲ high-value products	+20,562
Frozen Foods	flat	—	▼ North America cost	▼	−4,558
Other	▼	—	▼ strategic cost	—	−315

Healthcare was the marginal profit engine (+¥20.6B) on ABF volume AND a ~30% price increase — pricing power with near-zero demand elasticity. Seasonings grew through Japan price increases but faced overseas raw-material cost inflation. Frozen Foods was the drag (North America).

④ Demand structure / downstream

Segment cyclicality profile

Seasonings & Foods

Defensive

Frozen Foods

Semi-def.

Healthcare / ABF

Cyclical (AI)

ABF demand is concentrated on the AI / high-performance-computing cycle — the group's highest-growth but most single-cycle-dependent asset.

Geographic revenue mix (FY2026)

Japan

31%

Asia (ex-Japan)

34%

Americas

24%

Europe/Africa

11%

Overseas ratio ~64%. Diversified staple base cushions the ABF/AI-cycle concentration.

⑤ Capacity / capex / mid-term plan

ABF capacity — the binding constraint

2 plants (Kawasaki, Gunma); >200万㎡/month, running at full capacity.
May 2026: land acquired in Gifu for a 3rd plant (construction 2028, production ~2032).
Committed ≥¥25B capex by 2030 to raise ABF capacity ~50%; cloud customers pre-paying/locking long-term capacity.
Supply-demand gap: ~10% (2026H2) → 21% (2027) → 42% (2028) → pricing power persists for years.

2030 ASV Roadmap targets

Business-profit CAGR >10% (FY21–30); food : amino-science = 1:1 by 2030.
ROIC ~17%, ROE ~20%, EPS ~3× FY2022.
Frozen foods: sales CAGR ~3% / BP CAGR ~7% (turnaround, not growth).
Healthcare/ICT new value: ~¥120B sales / ~¥50B BP by 2030 (FY2020 base).
R&D ~¥30.9B (FY24), >36% to Healthcare; Forge Biologics (gene-therapy CDMO) acquired.

⑥ Competition & risk

Risk	Severity	Description / sensitivity
ABF single-cycle dependence	High	Revenue tied to AI/HPC capex; an AI-capex correction hits volumes directly.
Customer concentration	Medium-High	ABF customers (substrate/TSMC) and end users (US/Taiwan) geographically concentrated; not fully disclosed.
Technology shift (glass substrate)	Medium	Post-2028 glass-substrate adoption could alter ABF demand (management argues ABF content rises with more layers).
FX	Medium	~64% overseas revenue; yen strength below the 145/USD planning rate is a sales/profit headwind.
Frozen Foods margin	Medium	North America hit by US tariffs/import-cost inflation; profit halved in FY2026.
MSG price competition	Low-Medium	Chinese MSG producers could trigger a price war in commodity umami.
One-off earnings distortion	Low	¥40.6B property-sale gain inflated FY2026 reported profit — not run-rate.

⑦ Governance & capital-return signals

Shareholder actions

Activist Palliser Capital (London) — major stake, demanded ABF price hikes & electronics separation; management complied on pricing and raised guidance.
New tech-background CEO 中村茂雄 (first non-food CEO, ex-ABF developer) driving "高速開発システム" (high-speed development).
Buyback up to 30M shares / ¥80B (Nov 2025); ~9.7M shares / ¥37.6B by Apr 2026, to be cancelled.
Divest & acquire: Malaysia Ajinomoto full-subsidiarization (Jun 2026); Altea CDMO sale; Forge Biologics acquisition.

ROE / profitability trajectory

ROE (FY26)

17.5%

ROE (FY24)

9.5%

ROIC (FY26)

10.0%

ROE rebounded to ~17.5% in FY2026 on higher profitability and buybacks; 2030 target ROE ~20%.

05 · Segment Structure

Segment Structure

Segment revenue (external, ¥M)

Segment	FY22	FY23	FY24	FY25	FY26
Seasonings & Foods	664,237	775,021	846,977	896,012	936,926
Frozen Foods	221,702	267,237	281,870	289,388	290,308
Healthcare & Others	251,259	299,670	294,564	328,397	341,504
Other	12,171	17,185	15,819	16,758	14,979

Segment business profit (¥M)

Segment	FY22	FY23	FY24	FY25	FY26
Seasonings & Foods	81,269	84,800	111,550	134,129	143,036
Frozen Foods	−678	2,013	9,576	13,015	8,457
Healthcare & Others	43,362	48,657	24,386	45,640	66,202
Other	−3,038	−130	2,167	6,379	6,064
Unalloc. common cost	—	—	—	−39,862	−42,597

FY2026 segment revenue mix

⚠️ Segment comparability: From FY2025, Ajinomoto stopped allocating company-wide common costs into segments (shown separately as "Unalloc. common cost"). FY2022–FY2024 segment profit includes allocated common costs, so segment rows are NOT directly comparable across the FY2024→FY2025 boundary. FY2025 figures shown are the restated values from the FY2026 report.

06 · Anomaly Analysis

Anomaly Analysis

FY2025 net-profit dive High impact / low quality concern

Net profit fell to ¥70.3B (from ¥87.1B) despite record business profit — a ¥33.9B impairment (¥31.2B at Altea CDMO subsidiary) plus higher other operating expenses (¥50.3B) hit below the business-profit line. Cause: Altea goodwill/fixed-asset write-down. Underlying business profit still grew +7.9%.

FY2026 operating-profit spike One-off

Operating profit jumped +75% to ¥199.4B, but includes a ¥40.6B gain from selling the head-office building. Exclude it and operating profit (~¥159B) is in line with business profit (¥181B). Use business profit for run-rate valuation.

Segment comparability break Method change

From FY2025, company-wide common costs are no longer allocated into segments (shown as a separate adjustment). The FY2024→FY2025 jump in Seasonings/Healthcare segment profit is partly a reporting artifact, not pure underlying growth.

Healthcare profit volatility Impairment-driven

Healthcare BP collapsed to ¥24.4B in FY2024 (impairment) then surged to ¥66.2B in FY2026 (+45%). FY2026 is the first clean read of the ABF-driven acceleration.

Frozen Foods reversal Structural

Frozen BP fell −35% (¥13.0B → ¥8.5B) on North America decline (US tariff/import-cost inflation). The FY2025 recovery proved non-durable — the structurally weakest segment.

Dividend / payout distortion Presentation artifact

The payout ratio swing (57% → 17%) is largely a 2-for-1 stock split (Apr 2025) adjustment plus the FY2026 one-off profit gain. Underlying payout is ~30–40%; total dividends rose from ¥39.1B (FY25) to ¥43.2B (FY26).

07 · Valuation

Valuation

Peer comparison (P/E, TTM)

Ajinomoto (2802)

~39×

Kikkoman (2801)

~28×

Kewpie (2809)

~22×

Nichirei (2871)

~20×

Ajinomoto trades at a premium to packaged-food peers, justified by the ABF semiconductor growth option + activist catalysts.

Scenario-based target (¥)

Scenario	Fwd P/E	Target (¥)	Upside
Conservative	28×	5,600	+1%
Base	34×	6,800	+22%
Target	38×	7,600	+37%

Assumes ~¥200 FY2027E EPS. Base case reflects continued ABF volume+price growth and healthcare margin expansion.

Key valuation inputs: current ¥5,566; TTM P/E ~39×; P/B ~7×; dividend yield ~0.9%; analyst avg target ~¥6,032; Morningstar raised FV ~20% on ABF strength.

08 · Catalysts

Catalysts — next 12 months

FY2027 guidance delivery / upgrade: Q1 revenue +13% YoY (yen weakness + ABF); company already raised FY2026 guidance — further raises if ABF supply stays tight.
ABF price-hike pass-through (Q3 2026): the ~30% increase flows through Healthcare segment profit in H2 FY2026 / FY2027.
Buyback execution: ~¥80B authorization, ~¥37.6B done; continued open-market purchases support EPS and share price.
Activist follow-through (Palliser): any progress on electronics-materials separation / higher returns = positive re-rating catalyst.
Gifu ABF plant milestone: construction start 2028 and any capacity/tech announcements.
Corporate actions: Malaysia Ajinomoto full-subsidiarization close; further M&A in CDMO/gene therapy.
FX: a weaker yen (above 145/USD) lifts overseas sales/profit and beats guidance.

09 · Risks

Risks

ABF cycle reversal — Healthcare contributes ~30% of group profit via a single AI-semiconductor cycle; an AI-capex correction would hit volumes and margins hard.

Customer / geographic concentration — ABF customers and end users concentrated in US/Taiwan; geopolitical/export-control risk and supply-chain concentration are real.

Technology shift — glass-substrate adoption (post-2028) could erode ABF's role; competitors (Sekisui, Chinese CBF/SIF players) target low-end share.

Valuation risk — ~39× TTM P/E is well above sector (~21×); the premium requires growth delivery; any ABF disappointment compresses the multiple.

FX / raw-material risk — ~64% overseas revenue; yen strength and input-cost inflation pressure overseas margin and the ¥1.723T sales target.

Frozen Foods margin — North America tariff/import-cost pressure; profit halved in FY2026 and could stay weak.

10 · Profit Quality

Profit Quality

Metric	FY22	FY23	FY24	FY25	FY26
Gross margin %	37.1	34.6	35.5	36.0	37.7
Business-profit margin %	10.5	10.0	10.3	10.4	11.4
Operating CF (¥M)	145,576	117,640	168,074	209,898	239,351
ROE %	11.4	12.8	9.5	11.9*	17.5
Dividend payout %	~37	~39	~44	~57	~17*
Net cash / (debt) (¥M)	—	—	—	—	net debt modest

Assessment: Profit quality is solid but noisy below the business-profit line. The cleanest operating measure — business profit — has risen every year and reached a record 11.4% margin. However, reported operating/net profit are distorted by one-offs (FY25 Altea impairment ¥33.9B; FY26 property gain ¥40.6B) and segment figures are affected by the FY2025 common-cost reallocation. Operating cash flow is strong and rising (¥239B in FY26). *ROE/payout FY25–26 partly reflect buybacks and the one-off gain.

11 · Conclusion

Conclusion — Buy, target ¥6,800

BUY Target ¥6,800 (vs current ¥5,566) · +22% upside Horizon: 12–18 months Conviction: High

Verdict: Ajinomoto is best understood not as a food company with a semiconductor sideline, but as a defensive staple annuity (Seasonings) cross-financing a quasi-monopoly AI-material growth option (ABF). The two are oppositely cyclical, making group earnings unusually resilient. Activist pressure is unlocking the ABF monopoly's pricing power, and buybacks support returns. We rate it BUY.

Bull & bear points

✓ Supporting

ABF >95% global share, ~100% high-end — near-total monopoly, no substitute.
~30% ABF price increase (May 2026) with near-zero demand elasticity.
ABF supply-demand gap 21% (2027) → 42% (2028); capacity at 100%, new plant ~2032.
Healthcare segment BP +45% YoY, functional-materials margin >50%.
Seasonings record 15.3% margin; defensive staple base.
Business profit grew every year to a record ¥181B / 11.4% margin.
Activist Palliser driving pricing & potential electronics separation.
Buyback ¥80B (¥37.6B done), shares to be cancelled.
2030 targets: BP CAGR >10%, ROIC ~17%, EPS ~3× FY22.
Strong and rising operating cash flow (¥239B FY26).

⚠ Caution

ABF is single-cycle (AI-capex) dependent — an AI correction hits hard.
Customer/geographic concentration (US/Taiwan) + geopolitical risk.
Glass-substrate technology shift post-2028 is a watch item.
~39× TTM P/E is a large premium to sector (~21×).
Frozen Foods (N. America) profit halved; structurally weak.
Reported earnings distorted by one-offs (FY25 impairment, FY26 property gain).
FX: yen strength below 145/USD is a headwind.
MSG price competition from Chinese producers.

Recommended action: Accumulate on weakness. Core long for investors seeking a defensive-staples base with an embedded high-growth AI-material option. Key monitor: ABF pricing/capacity, quarterly ABF demand, buyback pace, and any electronics-separation news.

For information only — not investment advice. Data from Ajinomoto FY2022–FY2026 有価証券報告書 (ima) and public market sources. Figures in ¥ million unless noted.